Abstract
The outcome for patients with recurrent and metastatic germ cell tumors can be dismal, and novel salvage therapies are required for these patients. Here we describe a case of metastatic germ cell tumor in which 30% of cells were positive for PD-L1. This tumor achieved a durable response to toripalimab, a monoclonal anti-PD-1 antibody. Follow-up for 36months post-treatment confirmed no disease progression. Continuous remission was maintained even when treatment was interrupted after 18months because of an immune-related adverse event (allergic rhinitis). Thus, toripalimab may be an alternative choice for salvage therapy in patients with recurrent and metastatic germ cell tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
